|
2010 |
To broaden biocatalysis platform offerings to the pharmaceutical industry, Cambrex acquires IEP GmbH; now Cambrex IEP. |
|
2009 |
Cambrex Karlskoga completes the addition of a new cGMP API production facility. |
|
2008 |
Cambrex expands their group of world class R&D chemists by acquiring Prosyntest; renamed Cambrex Tallinn. Steven M. Klosk is appointed to CEO while remaining President. Cambrex Charles City completes the construction of a high potency development center. |
|
2007 |
Cambrex exits the biologics market and re-focuses on small molecule APIs and intermediates at its three manufacturing facilities: Cambrex Karlskoga, Cambrex Profarmaco, and Cambrex Charles City. Cambrex Profarmaco completes the expansion of the R&D lab and the additions of a new purification department and warehouse. |
|
2003 |
The company dedicates itself to providing essential products and services that accelerate drug discovery, development and manufacturing of human therapeutics. |
|
2002 |
To support the Company's strategic emphasis on the growing opportunities in the life sciences industry, Cambrex launches a new corporate identity. Cambrex obtains DEA licensing for Controlled Substance API manufacturing. |
|
2001 |
Cambrex enters the biologics manufacturing market with the acquisition of two contract biopharmaceutical manufacturing facilities. The facilities produce purified bulk biologics and pharmaceutical ingredients from clinical to commercial scale. |
|
2000 |
Cambrex continues its growth into the life sciences and biologics industries through acquisitions of a chiral enzymatic catalyst business and a bioscience products facility in Belgium. |
|
1999 |
Cambrex enters the growing fields of molecular biology and proteomics through the acquisition of FMC Bioproducts business. In addition to bioscience, this acquisition further strengthens the API and advanced intermediates manufacturing capacity. |
|
1997 |
Cambrex enters the biologics market with the acquisition of BioWhittaker, a life sciences company that provides cell culture and endotoxin detection products. |
|
1994 |
Cambrex further penetrates the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry business, Nobel Chemicals AB and Profarmaco S.r.l. The business units are later renamed Cambrex Karlskoga and Cambrex Profarmaco. |
|
1991 |
The Company enters the life sciences arena with the acquisition of Salsbury Chemicals, a manufacturer of bulk intermediates and APIs, as well as high-level research in nitration chemistry, and Zeeland Chemicals, a producer of specialty intermediates and hydrogenation chemistry. |
|
1990 |
James A. Mack is appointed to President and CEO. Cambrex is listed on the New York Stock Exchange (NYSE). |
|
1987 |
The Company changes its name to Cambrex Corporation and becomes listed on the NASDAQ. |
|
1981 |
Originally named CasChem, the Company is founded with the castor oil and derivatives product lines are acquired from NL industries. |
